Meeting
2024 ASCO Breakthrough
The prognosis of pancreatic neuroendocrine tumors according to the WHO 2017 classification: The multi-center experience in Taiwan.
Authors
Wei-Pang Ho
Department of Hematology-Oncology, Chang Gung Memorial Hospital at Linkou and Chang Gung University College of Medicine, Taoyuan City, Taiwan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Gastrointestinal Cancer,Central Nervous System Tumors,Developmental Therapeutics,Genitourinary Cancer,Quality of Care,Healthcare Equity and Access to Care,Population Health,Viral-Mediated Malignancies
Sub Track
Real-World Evidence/Real-World Data
Citation
J Clin Oncol 42, 2024 (suppl 23; abstr 87)
DOI
10.1200/JCO.2024.42.23_suppl.87
Abstract #
87
Poster Bd #
F9
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Prognostic factors of overall (OS) and relapse-free survival (RFS) for patients with acute myeloid leukemia (AML) in remission after intensive chemotherapy (IC): Multivariate analyses from the QUAZAR AML-001 trial of oral azacitidine (Oral-AZA).
First Author: Gail J. Roboz
Poster
2017 Gastrointestinal Cancers Symposium
Impact of sarcopenia on survival outcomes in patients (pts) with metastatic gastric cancer (mGC).
First Author: Keiji Sugiyama
Poster
2015 Genitourinary Cancers Symposium
Treatment outcome of patients with intermediate- and poor-prognosis metastatic testicular cancer in the 2000s: A multicenter experience in Japan.
First Author: Takahiro Kojima
Poster
2014 Gastrointestinal Cancers Symposium
Survival outcomes of schirrhus gastric cancer treated by multidisciplinary treatments: Putative impact on prognosis by DCS NAC.
First Author: Keishi Yamashita